Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7329670B1 · kind B1 · utility
49Cited by
111References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 27, 1999 |
| Grant date | Feb 12, 2008 |
| Priority date | — |
| Expiry date | Dec 27, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The compounds are aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B where A is the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. The compounds inhibit raf kinase and are useful in the treatment of RAF kinase mediated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.